Hubert Y Pan1, Pamela K Allen1, Xin S Wang2, Eric L Chang3, Laurence D Rhines4, Claudio E Tatsui4, Behrang Amini5, Xin A Wang6, Nizar M Tannir7, Paul D Brown1, Amol J Ghia8. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer, Houston, Texas. 2. Department of Symptom Research, University of Texas MD Anderson Cancer, Houston, Texas. 3. Department of Radiation Oncology, University of Texas MD Anderson Cancer, Houston, Texas; Department of Radiation Oncology, USC Norris Cancer Center, Los Angeles, California. 4. Department of Neurosurgery, University of Texas MD Anderson Cancer, Houston, Texas. 5. Department of Diagnostic Radiology, University of Texas MD Anderson Cancer, Houston, Texas. 6. Department of Radiation Physics, University of Texas MD Anderson Cancer, Houston, Texas. 7. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer, Houston, Texas. 8. Department of Radiation Oncology, University of Texas MD Anderson Cancer, Houston, Texas. Electronic address: AJGhia@mdanderson.org.
Abstract
PURPOSE/OBJECTIVE(S): To perform a secondary analysis of institutional prospective spine stereotactic body radiation therapy (SBRT) trials to investigate posttreatment acute pain flare. METHODS AND MATERIALS: Medical records for enrolled patients were reviewed. Study protocol included baseline and follow-up surveys with pain assessment by Brief Pain Inventory and documentation of pain medications. Patients were considered evaluable for pain flare if clinical note or follow-up survey was completed within 2 weeks of SBRT. Pain flare was defined as a clinical note indicating increased pain at the treated site or survey showing a 2-point increase in worst pain score, a 25% increase in analgesic intake, or the initiation of steroids. Binary logistic regression was used to determine predictive factors for pain flare occurrence. RESULTS: Of the 210 enrolled patients, 195 (93%) were evaluable for pain flare, including 172 (88%) clinically, 135 (69%) by survey, and 112 (57%) by both methods. Of evaluable patients, 61 (31%) had undergone prior surgery, 57 (29%) had received prior radiation, and 34 (17%) took steroids during treatment, mostly for prior conditions. Pain flare was observed in 44 patients (23%). Median time to pain flare was 5 days (range, 0-20 days) after the start of treatment. On multivariate analysis, the only independent factor associated with pain flare was the number of treatment fractions (odds ratio = 0.66, P=.004). Age, sex, performance status, spine location, number of treated vertebrae, prior radiation, prior surgery, primary tumor histology, baseline pain score, and steroid use were not significant. CONCLUSIONS: Acute pain flare after spine SBRT is a relatively common event, for which patients should be counseled. Additional study is needed to determine whether prophylactic or symptomatic intervention is preferred.
PURPOSE/OBJECTIVE(S): To perform a secondary analysis of institutional prospective spine stereotactic body radiation therapy (SBRT) trials to investigate posttreatment acute pain flare. METHODS AND MATERIALS: Medical records for enrolled patients were reviewed. Study protocol included baseline and follow-up surveys with pain assessment by Brief Pain Inventory and documentation of pain medications. Patients were considered evaluable for pain flare if clinical note or follow-up survey was completed within 2 weeks of SBRT. Pain flare was defined as a clinical note indicating increased pain at the treated site or survey showing a 2-point increase in worst pain score, a 25% increase in analgesic intake, or the initiation of steroids. Binary logistic regression was used to determine predictive factors for pain flare occurrence. RESULTS: Of the 210 enrolled patients, 195 (93%) were evaluable for pain flare, including 172 (88%) clinically, 135 (69%) by survey, and 112 (57%) by both methods. Of evaluable patients, 61 (31%) had undergone prior surgery, 57 (29%) had received prior radiation, and 34 (17%) took steroids during treatment, mostly for prior conditions. Pain flare was observed in 44 patients (23%). Median time to pain flare was 5 days (range, 0-20 days) after the start of treatment. On multivariate analysis, the only independent factor associated with pain flare was the number of treatment fractions (odds ratio = 0.66, P=.004). Age, sex, performance status, spine location, number of treated vertebrae, prior radiation, prior surgery, primary tumor histology, baseline pain score, and steroid use were not significant. CONCLUSIONS: Acute pain flare after spine SBRT is a relatively common event, for which patients should be counseled. Additional study is needed to determine whether prophylactic or symptomatic intervention is preferred.
Authors: Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo Journal: CNS Oncol Date: 2017-07-18
Authors: Luluel Khan; Andrew Chiang; Liying Zhang; Isabelle Thibault; Gillian Bedard; Erin Wong; Andrew Loblaw; Hany Soliman; Michael G Fehlings; Edward Chow; Arjun Sahgal Journal: Support Care Cancer Date: 2015-03-10 Impact factor: 3.603
Authors: Rachit Kumar; Anick Nater; Ahmed Hashmi; Sten Myrehaug; Young Lee; Lijun Ma; Kristin Redmond; Simon S Lo; Eric L Chang; Albert Yee; Charles G Fisher; Michael G Fehlings; Arjun Sahgal Journal: Neurooncol Pract Date: 2015-07-27
Authors: Ehsan H Balagamwala; Mihir Naik; Chandana A Reddy; Lilyana Angelov; John H Suh; Toufik Djemil; Anthony Magnelli; Samuel T Chao Journal: J Radiosurg SBRT Date: 2018
Authors: Alfonso Gomez-Iturriaga; Jon Cacicedo; Arturo Navarro; Virginia Morillo; Patricia Willisch; Claudia Carvajal; Eduardo Hortelano; Jose Luis Lopez-Guerra; Ana Illescas; Francisco Casquero; Olga Del Hoyo; Raquel Ciervide; Ana Irasarri; Jose Ignacio Pijoan; Pedro Bilbao Journal: BMC Palliat Care Date: 2015-10-01 Impact factor: 3.234